Ticker Scorecard - SPRO Basics Company: Spero Therapeutics, Inc. IPO Date: November 2, 2017 Sector: Healthcare Industry: Biotech Market Cap: $45.3M Activated in VL: True Average Daily Range Avg Daily Range: $0.26 | 3.08% Avg Daily Range (30 D): $0.03 | 3.15% Avg Daily Range (90 D): $0.03 | 2.74% Institutional Daily Volume Avg Daily Volume: .43M Avg Daily Volume (30 D): .17M Avg Daily Volume (90 D): .23M Trade Size Avg Trade Size (Sh.): 240 Avg Trade Size (Sh.) (30 D): 478 Avg Trade Size (Sh.) (90 D): 425 Institutional Trades Total Inst.Trades: 86 Avg Inst. Trade: $1.8M Avg Inst. Trade (30 D): $.55M Avg Inst. Trade (90 D): $.55M Avg Inst. Trade Volume: .18M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.1M Avg Closing Trade (30 D): $M Avg Closing Trade (90 D): $M Avg Closing Volume: 298.25K     News Jan 10, 2025 @ 12:00 PM Spero Therapeutics Provides Business Update and An... Source: Spero Therapeutics Jul 3, 2024 @ 5:07 PM Spero Therapeutics Announces Inducement Grant Unde... Source: N/A Jun 24, 2024 @ 1:07 PM Denali Therapeutics (DNLI) Moves 5.8% Higher: Will... Source: Zacks Equity Research Jun 3, 2024 @ 8:05 PM Spero Therapeutics Announces Inducement Grant Unde... Source: Spero Therapeutics, Inc. May 16, 2024 @ 8:05 PM Spero Therapeutics to Participate in H.C. Wainwrig... Source: Spero Therapeutics, Inc. Financials   TTM Q3 2024 Q2 2024 Basic EPS $.08 $-.32 $-.33 Diluted EPS $.08 $-.32 $-.33 Revenue $ 106.46M $ 13.47M $ 10.2M Gross Profit $ $ $ Net Income / Loss $ 3.51M $ -17.15M $ -17.86M Operating Income / Loss $ -1.1M $ -18.59M $ -19.06M Cost of Revenue $ $ $ Net Cash Flow $ -.04M $ 12.76M $ -18.74M PE Ratio 10.39